Successful Chemotherapy for Diffuse Cystic Lung Metastases during Targeted Therapy with Osimertinib in a Patient with Non-Small-Cell Lung Cancer: A Literature Review and a Rare Case Report
Introduction: Diffuse lung cysts occur owing to several diseases; however, diffuse cystic lung metastases are very rare in the case of lung cancer. We report a rare case of diffuse cystic lung metastases from lung adenocarcinoma and reviewed previously reported cases of cystic lung metastases for lung cancer and determined their characteristics. Case Presentation: A 78-year-old Japanese woman with advanced lung adenocarcinoma was positive for the epidermal growth factor receptor gene mutation exon 21 L858R and had been treated with osimertinib. She presented with multiple bilaterally positioned thin-walled lung cysts and pneumothorax. Lung cysts were diagnosed as cystic lung metastases from lung cancer, and carboplatin, pemetrexed, and pembrolizumab were subsequently administered. All cysts markedly decreased in size, and some disappeared. Conclusion: Effective treatment methods for cystic lung metastases from lung cancer have not been reported. To our knowledge, this is the first case of cystic lung metastases that were successfully treated with chemotherapy.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Successful Chemotherapy for Diffuse Cystic Lung Metastases during Targeted Therapy with Osimertinib in a Patient with Non-Small-Cell Lung Cancer: A Literature Review and a Rare Case Report ; volume:16 ; number:1 ; year:2023 ; pages:1409-1414 ; extent:6
Case reports in oncology ; 16, Heft 1 (2023), 1409-1414 (gesamt 6)
- Creator
-
Matsukida, Akira
Ogawa, Takunori
Tanigaki, Tomomi
Serizawa, Yusuke
Nishimura, Masashi
Igarashi, Shunya
Kato, Yoshiki
Kawana, Akihiko
Kimizuka, Yoshifumi
- DOI
-
10.1159/000534711
- URN
-
urn:nbn:de:101:1-2023122800060997893130
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Matsukida, Akira
- Ogawa, Takunori
- Tanigaki, Tomomi
- Serizawa, Yusuke
- Nishimura, Masashi
- Igarashi, Shunya
- Kato, Yoshiki
- Kawana, Akihiko
- Kimizuka, Yoshifumi
Other Objects (12)
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
Bone Metastasis of Non-Small-Cell Lung Cancer Showing Pathological Complete Response to Osimertinib Monotherapy
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Exploration of lung mycobiome in the patients with non-small-cell lung cancer
Non-small-cell lung cancer
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
Bone Metastasis of Non-Small-Cell Lung Cancer Showing Pathological Complete Response to Osimertinib Monotherapy
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Exploration of lung mycobiome in the patients with non-small-cell lung cancer
Non-small-cell lung cancer
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
Bone Metastasis of Non-Small-Cell Lung Cancer Showing Pathological Complete Response to Osimertinib Monotherapy
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Exploration of lung mycobiome in the patients with non-small-cell lung cancer
Non-small-cell lung cancer
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer